Jpmorgan Chase & CO Intellia Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 649,054 shares of NTLA stock, worth $6.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
649,054
Previous 669,105 3.0%
Holding current value
$6.62 Million
Previous $15 Million 10.93%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$19.72 - $27.36 $395,405 - $548,595
-20,051 Reduced 3.0%
649,054 $13.3 Million
Q3 2024

Nov 08, 2024
SELL
$19.72 - $27.36 $395,405 - $548,595
-20,051 Reduced 3.0%
649,054 $13.3 Million
Q2 2024

Dec 26, 2024
BUY
$20.02 - $27.22 $401,421 - $545,788
20,051 Added 3.09%
669,105 $15 Million
Q2 2024

Aug 12, 2024
BUY
$20.02 - $27.22 $2.52 Million - $3.43 Million
125,998 Added 23.2%
669,105 $15 Million
Q1 2024

Dec 26, 2024
SELL
$23.82 - $32.8 $2.52 Million - $3.48 Million
-105,947 Reduced 16.32%
543,107 $14.9 Million
Q1 2024

May 10, 2024
SELL
$23.82 - $32.8 $2.22 Million - $3.05 Million
-93,010 Reduced 14.62%
543,107 $14.9 Million
Q4 2023

Dec 26, 2024
SELL
$23.16 - $32.34 $299,620 - $418,382
-12,937 Reduced 1.99%
636,117 $19.4 Million
Q4 2023

Feb 12, 2024
BUY
$23.16 - $32.34 $488,699 - $682,406
21,101 Added 3.43%
636,117 $19.4 Million
Q3 2023

Nov 14, 2023
SELL
$31.62 - $45.78 $1.21 Million - $1.75 Million
-38,334 Reduced 5.87%
615,016 $19.4 Million
Q2 2023

Aug 11, 2023
SELL
$34.58 - $46.03 $614,901 - $818,505
-17,782 Reduced 2.65%
653,350 $26.6 Million
Q1 2023

May 18, 2023
BUY
$33.3 - $44.82 $3.66 Million - $4.93 Million
109,960 Added 19.59%
671,132 $25 Million
Q1 2023

May 11, 2023
SELL
$33.3 - $44.82 $3.38 Million - $4.55 Million
-101,445 Reduced 15.31%
561,172 $20.9 Million
Q4 2022

Feb 13, 2023
BUY
$33.21 - $62.69 $722,981 - $1.36 Million
21,770 Added 3.4%
662,617 $23.1 Million
Q3 2022

Nov 14, 2022
SELL
$53.92 - $71.7 $87,188 - $115,938
-1,617 Reduced 0.25%
640,847 $35.9 Million
Q2 2022

Aug 11, 2022
BUY
$38.49 - $76.21 $557,912 - $1.1 Million
14,495 Added 2.31%
642,464 $33.3 Million
Q1 2022

May 11, 2022
SELL
$58.27 - $118.99 $2.35 Million - $4.81 Million
-40,398 Reduced 6.04%
627,969 $45.6 Million
Q4 2021

Feb 10, 2022
BUY
$100.76 - $138.36 $17.6 Million - $24.2 Million
174,640 Added 35.37%
668,367 $79 Million
Q3 2021

Nov 12, 2021
BUY
$132.37 - $176.78 $65.4 Million - $87.3 Million
493,727 New
493,727 $66.2 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $775M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email